Health Problems

Study questions the benefits of abdominal aortic aneurysm screening in men

Screening for abdominal aortic aneurysm—swelling of the major artery in the abdomen, which can cause sudden death if it ruptures—may not substantially reduce deaths from the condition, according to a Swedish cohort study of more than 130000 men published in The Lancet. The findings question the need for the screening, which is also conducted in the UK and USA.

In recent years, the number of cases of abdominal aortic aneurysm have decreased significantly, which may alter the benefits and harms of the screening.

In the study, the authors estimate how many deaths were avoided as a result of screening, how many people were overdiagnosed, and how many people were treated when they did not need to be.

Overdiagnosis is the detection of swelling in the artery that would never have caused symptoms in a person’s lifetime, nor caused their death. This can lead to unnecessary psychological distress, and mean that people undergo needless surgery. The surgery for abdominal aortic aneurysm is a complex operation in which the swelling of the major artery in the abdomen is replaced with a graft. The surgery has a risk of serious complications such as stroke, myocardial infarction, amputation, renal failure, and even death.

Screening for abdominal aortic aneurysm is available in Sweden, the UK and USA, and is offered to men when they turn 65 years old. It involves an ultrasound scan of the abdomen to measure the size of the aorta. Men who have an aorta that is 30 millimetres wide or more are diagnosed with abdominal aortic aneurysm, and monitored regularly. Men with an aorta wider than 55 mm are offered preventative surgery.

The study followed 25265 men aged 65 years or older who were invited to screening between 2006-2009, and 106087 men who were not invited for screening but otherwise similar (matched control group). The researchers calculated how many men were diagnosed with an abdominal aortic aneurysm, how many underwent surgery, and how many men died from the condition. They also looked at overall trends for these factors for all men aged 40-99 years in Sweden, between 1985 and 2015.

Between 2000-2015, mortality from abdominal aortic aneurysm declined by 70% across Sweden (from 36 to 10 deaths per 100000 men aged 65-74), with rates remaining similar in men who were and were not screened. In addition, screening did not substantially reduce mortality, with an estimated two deaths avoided for every 10000 men screened six years after screening. The difference was not statistically significant.

Screening was associated with significant harm from overdiagnosis and unnecessary treatment—six years after screening, 49 in every 10000 men screened were likely to have been overdiagnosed, and 19 of these men were likely to have undergone needless surgery.

As a result, the authors conclude that abdominal aortic aneurysm screening had only a minor effect on mortality, and instead suggest that the lower mortality from abdominal aortic aneurysm may be caused by declining smoking rates.

They warn that the harms of screening may outweigh the benefits, and question its continued use. They also note that many cases are identified outside of the screening programme, through opportunistic testing and identification.

“Previously, the balance between the benefits and harms of screening programmes for abdominal aortic aneurysm was unclear as the major harms had not been adequately considered. Our new findings suggest that this screening programme may be outdated, because the number of deaths from abdominal aortic aneurysm has been greatly reduced, likely due to lower smoking rates,” says lead author Dr. Minna Johansson, University of Gothenburg, Sweden. “As a result, the harms of this screening appear to outweigh the benefits, and our findings question the continued use of screening for abdominal aortic aneurysm in men. The results from this study are likely to be applicable to countries with similar trends in smoking rates and abdominal aortic aneurysm, which applies to many Western countries, for example the UK.”

The authors note some limitations, including that the follow-up of six years may not capture the full effect of screening, potentially underestimating the benefits and overestimating the harms. However, the authors do not believe that this would significantly change their conclusions.

Source: Read Full Article